Please check your internet connection and try again.
**Tus%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520qd (Tussionex Pennkinetic)**
## Overview
Tussionex is an extended-release combination product containing hydrocodone and chlorpheniramine. Hydrocodone is an opioid agonist that acts as a cough suppressant. Chlorpheniramine is a first-generation antihistamine that also possesses anticholinergic properties.
## Primary Indications
* Symptomatic relief of cough and cold symptoms.
## Adult Dosing
* **Usual Adult Dose:** 5 mL every 12 hours.
* **Maximum Dose:** Not explicitly stated in product literature for typical use, but caution should be exercised due to opioid and antihistamine effects. Individual institutional protocols may define maximums.
## Pediatric Dosing
* Tussionex is **not recommended** for use in pediatric patients under 6 years of age due to the risk of potentially fatal respiratory depression.
* Dosing for children aged 6 to 12 years may vary based on specific protocols and should be determined by a healthcare provider. Precise pediatric dosing information is often not standardized and may require careful titration and monitoring.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is recommended, but caution and close monitoring are advised.
* **Hepatic Impairment:** No specific dose adjustment is recommended, but caution and close monitoring are advised.
* **Elderly:** Use with caution, as elderly patients may be more sensitive to the adverse effects.
## Contraindications
* Patients with known hypersensitivity to hydrocodone or chlorpheniramine.
* Patients with respiratory depression, severe asthma, or other conditions where the use of opioids is contraindicated.
* Children under 6 years of age.
* Concurrent use with MAO inhibitors or within 14 days of stopping an MAO inhibitor.
## Adverse Effects
* **Common:** Sedation, dizziness, constipation, nausea, vomiting, dry mouth, blurred vision, confusion.
* **Serious:** Respiratory depression, hypoventilation, opioid-induced constipation, serotonin syndrome (with concomitant serotonergic agents), neonatal withdrawal syndrome (if used chronically during pregnancy).
## Key Drug Interactions
* **CNS Depressants (alcohol, benzodiazepines, other opioids, sedatives):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **MAO Inhibitors:** Risk of hypertensive crisis or severe CNS depression.
* **Serotonergic Agents (SSRIs, SNRIs, triptans):** Increased risk of serotonin syndrome.
* **Anticholinergic Agents:** Additive anticholinergic effects (e.g., urinary retention, constipation, dry mouth).
## Monitoring
* Assess for effectiveness in cough suppression.
* Monitor for signs of CNS depression (sedation, respiratory rate).
* Monitor bowel function for constipation.
* Assess for signs of hypersensitivity or adverse reactions.
## Clinical Pearls
* Tussionex has an extended-release formulation, meaning it should not be crushed, chewed, or broken to avoid rapid release of the active ingredients.
* Be aware of the potential for abuse and dependence associated with hydrocodone.
* Due to the anticholinergic properties of chlorpheniramine, caution should be exercised in patients with glaucoma or urinary retention.
***
*This information is intended for clinical use and does not replace the need to consult the most current prescribing information and institutional protocols.*
